ICARES Medicus Valuation

Q: What is the Fair Price of 6612 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6612 (NT$125.5) is trading above our estimate of [[fair value]] (NT$3.9)

Is 6612 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6612 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6612 (NT$125.5) is trading above our estimate of fair value (NT$3.9)

Significantly Below Fair Value: 6612 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6612?

Key metric: As 6612 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6612. This is calculated by dividing 6612's market cap by their current earnings.
What is 6612's PE Ratio?
PE Ratio	81.8x
Earnings	NT$66.08m
Market Cap	NT$5.41b

6612 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.6x
Enterprise Value/EBITDA	36.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 6612's PE Ratio compare to its peers?

The above table shows the PE ratio for 6612 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23x
1786 SciVision Biotech	30.4x	n/a	NT$6.6b
4126 Pacific Hospital Supply	15.6x	5.6%	NT$6.4b
4129 United Orthopedic	20.8x	n/a	NT$9.3b
6747 Brighten Optix	25.5x	n/a	NT$3.8b
6612 ICARES Medicus	81.8x	n/a	NT$5.4b

Price-To-Earnings vs Peers: 6612 is expensive based on its Price-To-Earnings Ratio (81.8x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does 6612's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 6612 is expensive based on its Price-To-Earnings Ratio (81.8x) compared to the TW Medical Equipment industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is 6612's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6612 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	81.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6612's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.0b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$212.50

-1.4%

-27.0%

Pacific Hospital Supply

NT$6.4b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$88.60

-0.3%

5.2%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$139.00

0.4%

3.0%